Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMounjaro vs Wegovy: what the clinical evidence and real-world switching experiences show
You've read the reviews and they're all over the place, here's why that happens
Picture this: you've been on Mounjaro for six months, lost a meaningful amount of weight, but your supply has been disrupted and your pharmacist suggests Wegovy as a bridge. Or you've been on Wegovy for a year and your results have plateaued, so someone in your support group recommends you ask about tirzepatide. You search for reviews and find wildly contradictory accounts, people who loved one and found the other almost intolerable, and vice versa.
That scatter isn't random. Mounjaro activates two gut-hormone receptors (GIP and GLP-1 together), while Wegovy works on the GLP-1 pathway alone. The different receptor profiles mean appetite suppression, gastrointestinal tolerance and the pattern of weight loss can feel distinct between the medicines, even if the broad side-effect categories overlap. A detailed comparison of their mechanisms helps unpick why the same dose escalation schedule can land very differently for two people with similar BMIs.
A common misconception worth putting to rest gently: that one medicine is simply "stronger" than the other in all circumstances. Trial data shows tirzepatide produces greater average weight reduction in head-to-head testing, but average results don't predict individual responses. Some people lose more on semaglutide. Some tolerate it considerably better. If you want to see how others have navigated this uncertainty, reading accounts from people who have changed from Mounjaro to Wegovy shows just how wide that spread of experience can be. Reviews reflect this spread, they're not all measuring the same thing.
What the head-to-head evidence actually says about Mounjaro versus Wegovy
The strongest direct evidence comes from the SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, which compared tirzepatide against semaglutide 2.4mg in 751 adults with obesity over 72 weeks. Tirzepatide produced a greater average reduction in body weight. Separately, SURMOUNT-1 (also published in the New England Journal of Medicine) found approximately 20–21% average body-weight reduction at 15mg tirzepatide over 72 weeks among thousands of participants. The STEP 1 trial for semaglutide 2.4mg showed around 15% average reduction over 68 weeks.
Those numbers matter, but they carry important caveats. SURMOUNT-5 was open-label (participants knew which medicine they were taking), and real-world reviews include people at many different doses, with many different starting points. For a structured side-by-side look at those trial figures, the comparison page covers eligibility, mechanism and results in one place.
It's also worth noting that the semaglutide story keeps developing. The MHRA approved a 7.2mg maintenance dose of Wegovy (and a dedicated single-dose 7.2mg pen in April 2026) with trial data suggesting approximately 20.7% average weight loss at that higher dose, which narrows the gap with tirzepatide 15mg. Cost and format differences are worth factoring in alongside the efficacy picture.
| Factor | Mounjaro (tirzepatide) | Wegovy (semaglutide) |
|---|---|---|
| Mechanism | Dual GIP + GLP-1 receptor agonist | GLP-1 receptor agonist |
| Average weight loss (clinical trial, highest maintenance dose) | ~20–21% over 72 weeks at 15mg [SURMOUNT-1, NEJM] | ~15% over 68 weeks at 2.4mg; ~20.7% at 7.2mg [STEP 1, NEJM; MHRA 2026] |
| UK licence for weight management | Yes (BMI ≥30, or ≥27 with a weight-related condition) | Yes (BMI ≥30, or ≥27 with a weight-related condition) |
| Dose form | Once-weekly subcutaneous injection (KwikPen) | Once-weekly subcutaneous injection; oral tablet (25mg) approved June 2026 |
| NICE recommendation | TA1026 (December 2024, updated September 2025) | TA875 (March 2023, max 2 years, specialist services) |
Switching between the two: what people who've changed describe, and what the prescriber considers
People who move from Mounjaro to Wegovy often report that the GI adjustment period restarts to some degree, nausea, changes in appetite rhythm, and digestive sensitivity can resurface as the body adapts to the different receptor profile. That's not unusual and usually settles, but it's one reason reviews of the switch process read so differently: someone who switched mid-titration versus someone who had reached a stable maintenance dose will have very different experiences to report.
Going the other direction, people moving from Mounjaro to Wegovy sometimes mention that the appetite-suppression pattern feels less pronounced initially, particularly if they were at a high tirzepatide dose. Others find semaglutide suits their GI tolerance better. Neither direction of travel is predictable from reviews alone.
A prescriber considering a switch will look at why the change is happening (supply, side effects, lack of response, cost, or clinical factors) and at what dose was reached on the original medicine. They'll also check contraception arrangements, since tirzepatide specifically can reduce absorption of oral contraceptives during the first four weeks of treatment and after each dose increase, making an additional non-oral method advisable. More detail on how the swapping process works clinically is covered in our switching guide. The NHS also sets out relevant considerations on the NHS England weight-management injections page.
Which medicine suits you is a clinical decision our prescribers make with you, based on your health history, your current dose, and what you're trying to achieve. Start your free consultation and a GPhC-registered prescriber will review your case the same day.
Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.